CU20170120A7 - Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores - Google Patents

Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores

Info

Publication number
CU20170120A7
CU20170120A7 CUP2017000120A CU20170120A CU20170120A7 CU 20170120 A7 CU20170120 A7 CU 20170120A7 CU P2017000120 A CUP2017000120 A CU P2017000120A CU 20170120 A CU20170120 A CU 20170120A CU 20170120 A7 CU20170120 A7 CU 20170120A7
Authority
CU
Cuba
Prior art keywords
tiadiazol
immunomodulators
oxadiazol
substituted compounds
inhibiting
Prior art date
Application number
CUP2017000120A
Other languages
English (en)
Inventor
Seetharamaiah Setty Sudarshan Naremaddepalli
Muralidhara Ramachandra
Pottayil Govindan Nair Sasikumar
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of CU20170120A7 publication Critical patent/CU20170120A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

<p>La presente invención hace referencia a compuestos 1,3,4 - oxadiazol y tiadiazol de fórmula (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>útiles para inhibir la vía de señalización de muerte celular programada 1 (PD-1) y/o para tratar trastornos mediante la inhibición de una señal de inmunosupresión inducida por PD-1, PD-L1 o PD-L2.</p>
CUP2017000120A 2015-03-10 2016-03-08 Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores CU20170120A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1179CH2015 2015-03-10
PCT/IB2016/051299 WO2016142852A1 (en) 2015-03-10 2016-03-08 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators

Publications (1)

Publication Number Publication Date
CU20170120A7 true CU20170120A7 (es) 2018-06-05

Family

ID=56879298

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000120A CU20170120A7 (es) 2015-03-10 2016-03-08 Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores

Country Status (16)

Country Link
US (1) US20180044304A1 (es)
EP (1) EP3267999A4 (es)
JP (1) JP2018507885A (es)
KR (1) KR20170123680A (es)
CN (1) CN107405336A (es)
AU (1) AU2016230812A1 (es)
BR (1) BR112017019306A2 (es)
CA (1) CA2979145A1 (es)
CU (1) CU20170120A7 (es)
EA (1) EA201791629A1 (es)
HK (1) HK1243339A1 (es)
IL (1) IL254046A0 (es)
MX (1) MX2017011614A (es)
PH (1) PH12017501452A1 (es)
SG (1) SG11201706900YA (es)
WO (1) WO2016142852A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
RS57559B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori
MY196130A (en) 2015-03-10 2023-03-16 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
WO2017176965A1 (en) 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CN108395443B (zh) * 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN109096219B (zh) * 2017-06-20 2023-03-21 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
KR20200068659A (ko) 2017-10-11 2020-06-15 오리진 디스커버리 테크놀로지스 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR20200108846A (ko) * 2018-01-12 2020-09-21 오리진 디스커버리 테크놀로지스 리미티드 Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN111057069B (zh) * 2018-10-16 2024-01-26 武汉光谷通用名药物研究院有限公司 一种环状化合物、其应用及组合物
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN111100086B (zh) * 2018-10-25 2022-07-01 南京圣和药业股份有限公司 1,3,4-噁二唑-2-环丁基类化合物及其制备方法
WO2020083336A1 (zh) * 2018-10-25 2020-04-30 南京圣和药业股份有限公司 1,3,4-噁二唑-2-环丁基类化合物及其制备方法和应用
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020132560A2 (en) 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN115835909A (zh) 2020-05-05 2023-03-21 泰昂治疗公司 大麻素受体2型（cb2）调节剂和其用途
CN114507227A (zh) * 2020-11-17 2022-05-17 中国医学科学院药物研究所 苯并异噻唑类化合物、及其制法和药物组合物与用途
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264315A1 (en) * 2007-07-26 2009-10-22 Texas A&M University System Dipeptide mimics, libraries combining two dipeptide mimics with a third group, and methods for production thereof
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012168944A1 (en) * 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
RS57559B1 (sr) * 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori

Also Published As

Publication number Publication date
EP3267999A4 (en) 2018-07-25
US20180044304A1 (en) 2018-02-15
CA2979145A1 (en) 2016-09-15
JP2018507885A (ja) 2018-03-22
PH12017501452A1 (en) 2018-01-15
EP3267999A1 (en) 2018-01-17
KR20170123680A (ko) 2017-11-08
IL254046A0 (en) 2017-10-31
WO2016142852A1 (en) 2016-09-15
AU2016230812A1 (en) 2017-09-07
HK1243339A1 (zh) 2018-07-13
MX2017011614A (es) 2018-03-23
EA201791629A1 (ru) 2018-02-28
BR112017019306A2 (pt) 2018-05-08
SG11201706900YA (en) 2017-09-28
CN107405336A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
CU20170120A7 (es) Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores
CU24509B1 (es) Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
CU20170118A7 (es) Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores
CU20170117A7 (es) COMPUESTOS TIADIAZOL y 1,3,4-OXADIAZOL 3-SUSTITUIDOS COMO INMUNOMODULADORES
CU20170116A7 (es) Compuestos cíclicos terapéuticos como inmunomoduladores
CY1120769T1 (el) Παραγωγα 1,3,4-οξαδιαζολιου και 1,3,4-θειαδιαζολιου ως ανοσοτροποποιητες
CY1120899T1 (el) Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
EA202090087A2 (ru) 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов